Akceso’s ‘Evidence-based Asset Valuation’ methodology
What the three-part evidence-gathering method includes and how it helps to achieve both patient- & public health benefit and long-term economic success.
András Incze
How a hostage negotiator can inspire business leaders?
Read the thoughts of András Incze related to the Advanced High-Performance Leadership (HPL) program led by Professor George Kohlrieser.
External Reference Pricing may have negative effects globally? – research article in Frontiers
This 5 years of research explores how external reference pricing (ERP, or also called as IRP – International Reference Pricing) is used to set pharmaceutical prices to improve affordability, but how its application may have negative consequences on patient access across certain countries.
We Look Back To A Remarkable Year 2021
We are happy to share with you the blog post of András Incze, CEO of Akceso Advisors on what was accomplished, how we made an impact with our international team in these challenging times and lived up again to our promise.
The Essence of 17 Years in Marathon Running
4 good reasons of running marathon: Read thoughts of András Incze about how marathon running became a passionate habit for him and how it reflects in Akceso.
Great Feedback For Our Recent Pricing & Reimbursement Project
“I am really pleased with the outcome…. and seldom agree so quickly with
No International Reference Pricing for drugs in the US – good news for patients in the US and worldwide
The US Government just published its “Comprehensive Plan for Addressing High Drug Prices”. It lists a number of initiatives and ideas, but does NOT mention is International Reference Pricing – and this is good news for patients in the US and worldwide (and for manufacturers, too). – Read the Akceso Advisors reflection on a latest development in the US pharmaceuticals market based on Akceso Advisors’ research related to the impact of International Reference Pricing (IRP) on patient access and innovation.
